ArticleInvestigational new drugs2023

A phase 1b study of the allosteric extracellular FGFR2 inhibitor alofanib in patients with pretreated advanced gastric cancer.

Ilya Tsimafeyeu et al.PubMed ↗Publisher ↗

No numbers read from the abstract.